Drug intelligence / Profile preview

buzhong shibuchang

Development stage: Unknown
Lead developer: Chang Gung Memorial Hospital
Modality: Small Molecules
Administration: Oral

Overview

Buzhong Shibuchang is a Traditional Chinese Medicine (TCM) decoction developed by West China Hospital of Sichuan University for the management of Low Anterior Resection Syndrome (LARS) in patients following colorectal cancer surgery. LARS encompasses a range of bowel dysfunctions, including fecal urgency, increased frequency, and incontinence, which significantly impact quality of life. The formula is designed to tonify the middle jiao and regulate intestinal function, thereby improving anorectal coordination and stool consistency. It is currently being evaluated in clinical trials to establish its efficacy and safety as a non-invasive therapeutic option for post-operative recovery in rectal cancer patients.

Other names: Buzhong Shibuchang Decoction补中十补肠

Beyond the preview

Go deeper on buzhong shibuchang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buzhong shibuchang.

Explore the full profile